SCHEMBL30368445

SCHEMBL30368445

CC(=O)Nc1cc(NC(=O)Cc2ccccc2OC(F)(F)F)ccn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.51
CSF1R P07333 1/20 0.49
PDGFRB P09619 1/20 0.49
KIT P10721 1/20 0.49
PDGFRA P16234 1/20 0.49
FLT3 P36888 1/20 0.49
ANO1 Q5XXA6 6/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP3A4 P08684 2/20 0.45
AAK1 Q2M2I8 2/20 0.45
JAK2 O60674 1/20 0.45
JAK1 P23458 1/20 0.45
TYK2 P29597 1/20 0.45
MEN1 O00255 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45
RORC P51449 1/20 0.44
MAPK1 P28482 1/20 0.44
CSNK1D P48730 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29029237 0.86 NTRK1 (0.48) NTRK1ANO1SMN1; SMN2RORC
SCHEMBL30368259 0.84 ANO1 (0.66) NTRK1CSF1RPDGFRBKITPDGFRA
SCHEMBL30382576 0.81 NAMPT (0.50) NTRK1SMN1; SMN2MEN1TSHRKMT2A
SCHEMBL30368230 0.80 JAK2 (0.62) ANO1JAK2JAK1TYK2
SCHEMBL30368170 0.79 ANO1 (0.51) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL30285530 0.79 P2RX4 (0.53) NTRK1ANO1SMN1; SMN2
SCHEMBL26186498 0.79 P2RX4 (0.53) NTRK1ANO1SMN1; SMN2
SCHEMBL26186528 0.78 P2RX4 (0.50) NTRK1ANO1SMN1; SMN2
SCHEMBL30368264 0.78 JAK2 (0.55) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2182471 0.77 WNT3A (0.62) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4172146-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed
EP-4171744-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed